Transforming Disease Monitoring

Transforming disease monitoring for patients, providers, and society.

Imagine a future where a simple urine test can detect deadly diseases before they get out of control. A future when diseases can be intercepted and people don’t become patients. At Glympse Bio, we are working to turn this vision into a reality. Take a glimpse into that future, where we are taking a glimpse inside the body.


What We Do


Query the body, not a sample

By pioneering the latest advancements in science, engineering, and medicine, we have created a new class of activity sensors that query the body and report back clinically-relevant information. Our approach is designed to be safe, simple, fast, and noninvasive, providing detailed insights into disease activity in real-time including its onset, stage, and response to treatments.


Perfectly tunable 

Our precisely-engineered activity sensors can be customized to report on diseases, tissues, cells, and broad biological targets. Disease sites are tuned by customizing routes of delivery (e.g. intravenous, inhaled, subcutaneous, etc) and produce readouts compatible with a broad range of multiplexed analytical platforms (e.g., Mass Spectrometry, ELISA, etc).


Deep disease insights

Information-rich results provide unique clinical insights into disease activity of biological targets for single patients or populations. At the earliest stages, long before other diagnostic methods are able, we aim to gain a glimpse into the stage and progression of important, complex diseases, such as cancer, fibrosis, inflammation, and infections.


Our activity sensors are administered to patients and tailor-made to query the activity of key biological targets such as proteases – a class of enzymes that drive critical disease pathways. We are applying sophisticated machine learning algorithms to develop a proprietary, whole-genome database of enzymes and sensors capable of targeting all clinically-relevant proteases. Our technology platform is extendable to multifunctional enzymes including kinases, glycases, and lipases. 

Our lead program is Non-Alcoholic Steatohepatitis (NASH), estimated to impact 16 million people in the U.S. and over 100 million worldwide. Our development pipeline features programs in liver and lung diseases (representing over $5 billion in total addressable markets) with preclinical validation in 10+ additional diseases.

Glympse has a creative business model that blends the best of a diagnostic development and regulatory pathway, therapeutics go-to-market model, and a biology-rich data engine.


Who We Are

Founded in 2015, Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia. Glympse Bio is currently located at the LabCentral incubator in Cambridge, MA.

Our team is committed to enhancing our understanding of human disease. Our goal is to better serve the needs of patients, clinicians, researchers, drug developers, and payors.


Our Values


Our Team


Board of Directors

Strategic Advisor

Jeffrey Arnold, Ph.D.
CEO, Arnold Strategies

Clinical Advisors

Scott Friedman, M.D.
Chief, Division of Liver Diseases, Icahn School of Medicine, Mt. Sinai 

Rohit Loomba, M.D., MHSc.
Director of Hepatology; Vice Chief, Division of Gastroenterology, UCSD

Arun Sanyal, M.D.
Professor, Division of Gastroenterology, Hepatology & Nutrition, VCU 

Gyongzi Szabo, M.D., Ph.D., FAASLD
Vice Chair of Research, Dept of Medicine, UMass Medical School




Join Us

We are a dynamic and high energy team that believes anything is possible with great science and great people. We are all committed to solving global health problems, and unapologetic about our grand aspirations to do so. We are creative, nimble, problem-solvers who equally embrace learning and smart risk-taking. We have been told we are ‘impatient optimists’, a badge we wear proudly to translate vision into action. We also care for one another and are committed to each others’ success.

If you fit the Glympse Bio profile, come partner with us! We are actively building our team and recruiting industry partners to our cause.




Glympse Bio has a discovery engine and product platform that is changing the paradigm for drug development and discovery. We are already establishing collaborations with Pharma for predicting or monitoring drug response in clinical trials or for launched drugs.


Glympse Bio offers a disruptive approach to developing and delivering activity sensors that have superior attributes to the endogenous biomarkers available in nature. We can tune our in vivo sensors to achieve a desired sensitivity, specificity, delivery, and readout. Best of all, our platform comes packaged in a favorable device regulatory pathway and drug reimbursement model.


We have a customizable and scalable technology platform that can predict and monitor patient responses to therapy, to ensure that the right patient receives and responds to the right treatment.

Group image - 2 copy.jpg


We are looking for distinctive people to join our fabulous team. And we are growing rapidly!




Follow us on Twitter

Preview our feed below.

Press releases

We were in stealth mode…not anymore!


See what people are saying.


Shout outs to our team.